I 
115TH CONGRESS 
2D SESSION 
H. R. 7063 
To amend the Public Health Service Act to provide for and support liver 
illness visibility, education, and research, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
OCTOBER 12, 2018 
Ms. VELA´ZQUEZ (for herself, Ms. CLARKE of New York, Mr. VELA, Mr. 
MEEKS, Mr. CARSON of Indiana, Ms. MENG, Mr. ESPAILLAT, Ms. 
JAYAPAL, Ms. NORTON, Ms. HANABUSA, Mr. THOMPSON of Mississippi, 
Ms. GABBARD, and Mr. FITZPATRICK) introduced the following bill; 
which was referred to the Committee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act to provide for 
and support liver illness visibility, education, and re-
search, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Liver Illness Visibility, 
Education, and Research Act of 2018’’. 
SEC. 2. FINDINGS. 
Congress finds the following: 
VerDate Sep 11 2014 
02:42 Oct 17, 2018
Jkt 089200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7063.IH
H7063
dlhill on DSK3GLQ082PROD with BILLS
(8) Hepatitis B is a primary risk factor for de-
veloping liver cancer, and 1 in 4 of those chronically 
infected with hepatitis B develop cirrhosis, liver fail-
ure, or liver cancer. 
(9) Half of all individuals with hepatitis B in 
the United States are Asian-American or Pacific Is-
lander, though this group accounts for only 5 per-
cent of the U.S. population. 
(10) Among African immigrants in the United 
States, the prevalence of hepatitis B infection is ap-
proximately 1 in 10, and African immigrants make 
up 30 percent of those with chronic hepatitis B in-
fection in the United States. 
(11) Among Hispanic/Latino communities, liver 
cancer incidence and death rates are twice as high 
compared to the non-Hispanic White population. 
(12) Hispanics/Latinos are 60 percent more 
likely to die from viral hepatitis than non-Hispanic 
Whites. 
SEC. 3. LIVER CANCER AND DISEASE RESEARCH. 
Subpart 1 of part C of title IV of the Public Health 
Service Act (42 U.S.C. 285 et seq.) is amended by adding 
at the end the following new section: 
VerDate Sep 11 2014 
02:42 Oct 17, 2018
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H7063.IH
H7063
dlhill on DSK3GLQ082PROD with BILLS
‘‘SEC. 417H. LIVER CANCER AND DISEASE RESEARCH. 
‘‘(a) EXPANSION
AND COORDINATION
OF ACTIVI-
TIES.—The Director of the Institute shall expand, inten-
sify, and coordinate the activities of the Institute with re-
spect to research on liver cancer and other liver diseases. 
‘‘(b) PROGRAMS FOR LIVER CANCER.—In carrying 
out subsection (a), the Director of the Institute shall— 
‘‘(1) provide for an expansion and intensifica-
tion of the conduct and support of— 
‘‘(A) basic research concerning the etiology 
and causes of liver cancer; 
‘‘(B) clinical research and related activities 
concerning the causes, prevention, detection, 
and treatment of liver cancer; 
‘‘(C) control programs with respect to liver 
cancer, in accordance with section 412, includ-
ing community-based programs designed to as-
sist members of medically underserved popu-
lations (including women), low-income popu-
lations, or minority groups; and 
‘‘(D) information and education programs 
with respect to liver cancer, in accordance with 
section 413; 
‘‘(2) issue targeted calls for proposals from re-
search scientists for purposes of funding priority 
areas of liver cancer research; 
VerDate Sep 11 2014 
02:42 Oct 17, 2018
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H7063.IH
H7063
dlhill on DSK3GLQ082PROD with BILLS
‘‘(3) establish a special emphasis panel (as de-
fined by the National Institutes of Health) to review 
any proposal submitted pursuant to paragraph (2); 
and 
‘‘(4) based on reviews by the special emphasis 
panel under paragraph (3), select which proposals to 
fund or support. 
‘‘(c) INTER-INSTITUTE WORKING GROUP.—The Di-
rector of the Institute shall establish an inter-institute 
working group to coordinate research agendas focused on 
finding better outcomes and cures for liver cancer and 
other liver diseases, including hepatitis B. 
‘‘(d) GRANTS AND COOPERATIVE AGREEMENTS.— 
‘‘(1) IN GENERAL.—The Secretary may award 
grants and enter into cooperative agreements with 
entities for the purpose of expanding and supporting 
research on— 
‘‘(A) conditions known to increase an indi-
vidual’s risk of developing a major liver disease, 
such as liver cancer, hepatitis B, hepatitis C, 
nonalcoholic fatty liver disease, and cirrhosis of 
the liver; and 
‘‘(B) opportunities for preventative and di-
agnostic measures for such a disease, including 
VerDate Sep 11 2014 
02:42 Oct 17, 2018
Jkt 089200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H7063.IH
H7063
dlhill on DSK3GLQ082PROD with BILLS
the study of molecular pathology and biomark-
ers for early detection of such disease. 
‘‘(2) EXPERIMENTAL
TREATMENT
AND
PRE-
VENTION.—In the case of an entity that is a hospital 
or a health care facility, the Secretary may award a 
grant or enter into a cooperative agreement with 
such an entity for the purpose of supporting an ex-
perimental treatment or prevention program for liver 
cancer carried out by such entity. 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For purposes of carrying out this subsection, there 
is authorized to be appropriated $45,000,000 for 
each of fiscal years 2019 through 2023. Any 
amounts appropriated under this paragraph shall re-
main available until expended.’’. 
SEC. 4. LIVER CANCER AND DISEASE PREVENTION AND 
AWARENESS GRANTS. 
Subpart I of part D of title III of the Public Health 
Service Act (42 U.S.C. 254b et seq.) is amended by adding 
at the end the following new section: 
‘‘SEC. 330N. LIVER CANCER AND DISEASE PREVENTION AND 
AWARENESS GRANTS. 
‘‘(a) PREVENTION INITIATIVE GRANT PROGRAM.— 
‘‘(1) IN GENERAL.—The Secretary, through the 
Director of the Centers for Disease Control and Pre-
VerDate Sep 11 2014 
02:42 Oct 17, 2018
Jkt 089200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H7063.IH
H7063
dlhill on DSK3GLQ082PROD with BILLS
vention, may award grants and enter into coopera-
tive agreements with entities for the purpose of ex-
panding and supporting— 
‘‘(A) prevention activities (including pro-
viding screenings, vaccinations, or other pre-
ventative treatment) for conditions known to in-
crease an individual’s risk of developing a major 
liver disease, such as liver cancer, hepatitis B, 
hepatitis C, nonalcoholic fatty liver disease, and 
cirrhosis of the liver; and 
‘‘(B) activities relating to surveillance, 
diagnostics, and provision of guidance for indi-
viduals at high risk for contracting liver cancer 
and other liver diseases. 
‘‘(2) REPORT.—An entity that receives a grant 
or cooperative agreement under paragraph (1) shall 
submit to the Secretary, at a time specified by the 
Secretary, a report describing each activity carried 
out pursuant to such paragraph and evaluating the 
effectiveness of such activity in promoting prevention 
and treatment of liver cancer and other liver dis-
eases. 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For purposes of carrying out this subsection, there 
is authorized to be appropriated $90,000,000 for 
VerDate Sep 11 2014 
02:42 Oct 17, 2018
Jkt 089200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H7063.IH
H7063
dlhill on DSK3GLQ082PROD with BILLS
who care for such patients, and the general 
public; 
‘‘(B) model programs for cost effective and 
preventive patient care; and 
‘‘(C) training physicians and scientists in 
research on such diseases and complications; 
and 
‘‘(4) may perform research and participate in 
epidemiological studies and data collection relevant 
to liver diseases in order to disseminate such re-
search, studies, and data to the health care profes-
sion and to the public.’’. 
(h) ADVISORY COUNCIL SUBCOMMITTEES.—Section 
432 of the Public Health Service Act (42 U.S.C. 285c– 
6) is amended— 
(1) by striking ‘‘and a subcommittee on kidney, 
urologic, and hematologic diseases’’ and inserting ‘‘a 
subcommittee on kidney, urologic, and hematologic 
diseases, and a subcommittee on liver diseases’’; and 
(2) by striking ‘‘and kidney, urologic, and hem-
atologic diseases’’ and inserting ‘‘kidney, urologic, 
and hematologic diseases, and liver diseases’’. 
Æ 
VerDate Sep 11 2014 
02:42 Oct 17, 2018
Jkt 089200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6301
E:\BILLS\H7063.IH
H7063
dlhill on DSK3GLQ082PROD with BILLS